IGF-1 LR3 1mg Dosage Protocol

Educational guide for reconstitution and administration of IGF-1 LR3, a modified growth factor studied for tissue repair and anabolic effects.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (2 mL = 5 mg/mL)

Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 10 mg vial provides only 2–4 days of research material at these doses.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

Biological Action

IGF-1 LR3 represents a modified analog of insulin-like growth factor 1 with enhanced potency and extended half-life. The Long R3 modification reduces binding to IGF-binding proteins, allowing for greater bioavailability and anabolic effects.

As a potent growth factor analog, IGF-1 LR3 binds to IGF-1 receptors to stimulate cellular proliferation, protein synthesis, and tissue repair. The modified structure provides resistance to degradation and prolonged activity compared to native IGF-1.

IGF-1 LR3 has been studied extensively for its anabolic effects and role in supporting muscle growth, tissue recovery, and metabolic regulation in research contexts.

Potential Benefits & Side Effects

Findings from growth factor and tissue repair research.

• Potential to support tissue repair and protein synthesis in research settings
• May assist with muscle recovery and anabolic processes in research models
• Associated with cellular proliferation and growth factor signaling pathways
• Generally well tolerated; occasional mild injection reactions or localized effects
• Long-term human safety data not established; this compound remains investigational

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References